Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

NDAs, BLAs To Start Getting KASA Quality Risk Assessments After Successful Pilot With ANDAs

Executive Summary

Internal review system reduces US FDA’s administrative work for OPQ risk assessments; agency’s standards will not change, and sponsors will not need to modify applications. Advisory committee endorses expansion, which will roll out to different application types over several years.

You may also be interested in...



US FDA Ready To Move Forward On Developing Quality Management Maturity Rating System

The US FDA will begin work on operationalizing a Quality Management Maturity rating system following a public vote of confidence from its outside advisory committee. There are plenty of key details still to be worked out.

FDA Looks To Strengthen, Speed Drug Reviews With Flow Of Quality Data

Lift the burden of paper on drug quality reviews and the pace of innovation is no longer a problem for structural engineers or couriers – or even print or electronic document rooms. The focus at the US FDA is now on enabling direct transmission and analysis of critical quality data.

Structured reviews will accelerate ANDAs

Testing and implementing a more structured, computer-aided assessment process for abbreviated new drug applications (ANDAs) will enable the US Food and Drug Administration (FDA) to accelerate approvals on their first review cycle, according to Janet Woodcock, director of the Center for Drug Evaluation and Research (CDER).

Topics

Latest News
See All
UsernamePublicRestriction

Register

PS147308

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel